Some market commentary from today..
DJ CSL Target Price Cut 3.0% to A$326.00/Share by Goldman Sachs
CSL Price Target Cut 1.9% to A$265.00/Share by Morgan Stanley
Morgan Stanley now estimates that blood plasma collections by biopharma giant CSL will be down 25% in the June and September quarters, a worse decline than the 10% Morgan Stanley was previously predicting. Costs are also expected to rise by 5% per liter. Part of the problem is that Florida, California and Arizona, three states where the coronavirus recently accelerated, account for 30% of CSL's plasma-collection capability. Although collection centers are open, the pandemic and related social-distancing measures are making some donors wary. For Australia-based CSL, which reports fiscal 2020 earnings in August, the slowdown in plasma collections will be reflected in future sales, Morgan Stanley says. The investment bank has an equal-weight rating on CSL shares for now.
- Forums
- ASX - By Stock
- CSL
- Big sell call on CSL
Big sell call on CSL, page-25
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$308.05 |
Change
2.510(0.82%) |
Mkt cap ! $148.8B |
Open | High | Low | Value | Volume |
$307.94 | $309.48 | $306.35 | $254.8M | 840.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 268 | $307.92 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$308.23 | 139 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 307.350 |
1 | 100 | 307.150 |
1 | 16 | 307.080 |
2 | 200 | 307.000 |
1 | 50 | 306.800 |
Price($) | Vol. | No. |
---|---|---|
308.500 | 1481 | 2 |
308.600 | 146 | 1 |
309.000 | 165 | 1 |
309.400 | 100 | 1 |
309.500 | 208 | 3 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |